Voyageur Pharmaceuticals Ltd. (TSX-V: VM) announced on March 4, 2026, that independent laboratory testing has confirmed its barium sulfate active pharmaceutical ingredient (API) from the Frances Creek barite property meets or exceeds United States Pharmacopeia (USP) standards. The results, obtained through the Alberta Innovates AICE-Market Access Program, demonstrate purity averaging 98.8% BaSO4, surpassing the USP requirement of 97.5%. The API also passed all USP monograph tests, including those for heavy metals, particle size, and microbiological limits, with micronized particles achieving d50 values as low as 1.1 µm.
These findings allow Voyageur to advance to stage two of the Alberta Innovates program, which involves manufacturing barium contrast agents for a forthcoming clinical trial in patients. The trial, designed in accordance with Health Canada standards, will compare Voyageur's contrast products with current standard-of-care options for gastrointestinal Computed Tomography and fluoroscopic imaging. CEO Brent Willis stated, "These results are promising and represent a major de-risking milestone. We believe we have proven that our natural barite resource delivers high chemical purity, ideal particle size after micronization, and full USP compliance."
The clinical trial is expected to provide a comprehensive assessment of the company's products' performance, with successful outcomes anticipated to validate clinical performance, strengthen regulatory positioning, and accelerate market adoption. Full study completion is targeted for the fourth quarter of 2026. The trial results will also support Voyageur's FDA licensing applications, which began in the first quarter of 2026, and contribute to the prefeasibility and feasibility study for the Frances Creek project, expected by the fourth quarter of 2026.
Additionally, Voyageur announced the issuance of 378,651 Deferred Share Units (DSUs) to directors and a consultant, and 4,300,000 stock options to directors and officers, with exercise prices and vesting terms as per the company's equity compensation plan. The company also proposed issuing units for debt to an arm's length third party, subject to TSX Venture Exchange approval, to settle $100,000 in financial advisory services.
The company's vertically integrated strategy, from quarry to finished contrast media, aims to reduce reliance on imported or synthetic materials while improving cost efficiency and supply reliability. By developing its own natural barite resource, Voyageur seeks to replace synthetic barium sulfate with higher quality, lower cost imaging products, leveraging its Health Canada-licensed barium contrast products.
